No abstract available
Publication types
-
Editorial
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Angiogenesis Inhibitors / adverse effects
-
Angiogenesis Inhibitors / therapeutic use*
-
Animals
-
Antibodies, Monoclonal, Humanized / adverse effects
-
Antibodies, Monoclonal, Humanized / therapeutic use*
-
Antineoplastic Combined Chemotherapy Protocols / adverse effects
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Bevacizumab
-
Breast Neoplasms / blood supply
-
Breast Neoplasms / drug therapy*
-
Breast Neoplasms / mortality
-
Breast Neoplasms / pathology
-
Disease-Free Survival
-
Drug Approval
-
Evidence-Based Medicine
-
Female
-
Humans
-
Patient Selection
-
Quality of Life
-
Risk Assessment
-
Time Factors
-
Treatment Outcome
Substances
-
Angiogenesis Inhibitors
-
Antibodies, Monoclonal, Humanized
-
Bevacizumab